TEL: +86-21-50180596 Email: sales@biopharmaleader.com

Search

Contact Us

Tel: 0086 21 50180596

Fax: 0086 21 57758967

Mob: 0086 18721201413

E-mail:sales@biopharmaleader.com

Exhibition
Home > Exhibition > Content

Drug AZD9291 drug resistance NSCLC treatment TKI effect

Shanghai Biopharmaleader Co.,Ltd | Updated: Apr 19, 2016

A phase I study has found, a new Mutant-selective EGFR-TKI of AZD9291, with EGFR mutations in non-small cell lung cancer (NSCLC) patients could offer a promising new treatment options. About 50% in patients with tumors to shrink, the drug for patients with T790M mutations (detected in patients with 60%) effect is especially prominent and T790M mutations are the main cause of EGFR to treat drug-resistant.

Shanghai Biopharmaleader Co.,Ltd